O’Brien et al. [104] also reported CG responses in 66% of 47 CML patients in CP using HHT at a dose of 2.5 mg/m2 per day by constant infusion over 5 days in combination with IFN-α (intended dose 5 MU/m2 per day). This evidence concerns the gene IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive.